Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is taking immunotherapy to the next level in the fight against cancer and infectious diseases. They are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

Expert Comments:

Zacks Equity Research (9/7/16)
"Inovio Pharmaceuticals, Inc. is working on a preventive Zika vaccine. . .the company recently started a study on the vaccine in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. . .this is the second Zika vaccine study being conducted by Inovio and its collaborators. The first study is being conducted in sites across the U.S. and Canada with results due by year end. . .positive data would allow the company to meet regulatory authorities next year to determine the development path forward."

Jason Kolbert, Maxim Group (8/29/16)
"Inovio Pharmaceuticals Inc. announced the initiation of a small clinical study of its Zika vaccine, GLS-5700 (being developed with GeneOne Life Sciences), in Puerto Rico. It is estimated by the CDC that the Zika virus could infect more than 25% of the population of Puerto Rico by YE16. . .with the Zika virus spreading, including to the U.S., there remains an urgent need for a vaccine. Inovio continues to demonstrate that the company's DNA-based vaccine approach is safe and can rapidly transition to human studies. . .more data from the GLS-5700 studies should emerge later this year."

Ram Selvaraju, H.C. Wainwright & Co. (8/29/16)
"Inovio Pharmaceuticals Inc. announced that it has initiated a second clinical study of its preventive Zika vaccine, GLS-5700, in Puerto Rico, where Zika virus infections have been declared a public health emergency. This trial follows the company's first human trial of GLS-5700 in the U.S. and Canada, which was initiated in June 2016 and has fully enrolled and dosed 40 subjects. . .the successful development of a preventive Zika vaccine could meet the immediate needs of regions with high infection rates and provide additional upside to our current $17 price target, and reiterate our Buy rating."

Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal (skin) vaccination.
read more >
Jason Kolbert, Maxim Group (8/11/16)
"Inovio Pharmaceuticals Inc. announced that the phase I study of INO-4212 (Ebola vaccine) in healthy subjects will expand to include 125 more subjects to determine the best immunization strategy using intradermal vaccination. . .intradermal administration has been shown in several Inovio studies to be more effective at driving antigen-specific antibody responses. Antibodies are critical for clearing viral infections as they bind to and neutralize viral particles in the circulation, as well as viral antigens on infected cells to either kill them directly or label them for other immune cells to come in and kill them."

Ram Selvaraju, Rodman & Renshaw (8/9/16)
"Inovio Pharmaceuticals Inc. reported its Q2/16 financial results. Total revenue was $6.2M, beating our projection, due to an increase in development payments from the company’s DARPA Ebola grant. . .importantly, management has indicated that both the FDA and the European Medicines Agency (EMA) have provided an affirmative path for VGX-3100 to treat HPV-16/18-related high-grade cervical dysplasia in a pivotal Phase 3 registration study. . .This is encouraging news, in our view."

Charles Duncan, Piper Jaffray & Co. (8/8/16)
"Inovio Pharmaceuticals Inc [ended] the quarter with $134.5M in cash. We project this cash will fund pipeline progress through 1H18, inclusive of significant progress on the soon-to-start Phase 3 in cervical dysplasia and advancement to late-stage trials for a broadening set of infectious disease and oncology programs including Zika, MERS, cervical cancer (with MedImmune), and potentially other tumors. . .in advance of increasingly visible clinical progress expected across the platform over the next 12 months, we reiterate OW [overweight rating]."

Charles Duncan
Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company.
read more >

More Expert Comments

Experts Following This Company

Larry Biegelsen – Wells Fargo Securities
Jim Birchenough – BMO Capital Markets
Yi Chen, Managing Director of Equity Research – Rodman & Renshaw
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Dorman Followwill, Partner and Director EIA – Frost & Sullivan Inc
Jason Kolbert, Senior Analyst – Maxim Group
Chen Lin What Is Chen Buying? What Is Chen Selling?
Jason McCarthy, Analyst – Maxim Group
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Inovio Pharmaceuticals Inc. Content